MX2009011595A - Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90. - Google Patents

Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90.

Info

Publication number
MX2009011595A
MX2009011595A MX2009011595A MX2009011595A MX2009011595A MX 2009011595 A MX2009011595 A MX 2009011595A MX 2009011595 A MX2009011595 A MX 2009011595A MX 2009011595 A MX2009011595 A MX 2009011595A MX 2009011595 A MX2009011595 A MX 2009011595A
Authority
MX
Mexico
Prior art keywords
nucleic acids
antibody molecules
stress protein
novel antibody
protein hsp90
Prior art date
Application number
MX2009011595A
Other languages
English (en)
Inventor
James Burnie
Philipp Wechner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009011595A publication Critical patent/MX2009011595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se da a conocer un péptido scFv, el cual comprende un dominio VH y un dominio VL enlazados por un espaciador de aminoácidos. El dominio VH comprende una secuencia con una identidad de secuencia de cuando menos el 80 por ciento con la secuencia de la SEQ ID NO:64. El dominio VL comprende una secuencia con una identidad de secuencia de cuando menos el 80 por ciento con la secuencia de la SEO ID NO:66. El péptido scFv también comprende la sustitución o la supresión de un aminoácido en el dominio VH en la posición correspondiente a C28.
MX2009011595A 2007-04-27 2008-04-24 Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90. MX2009011595A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07107140 2007-04-27
EP07113353 2007-07-27
PCT/EP2008/055006 WO2008132134A1 (en) 2007-04-27 2008-04-24 Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90

Publications (1)

Publication Number Publication Date
MX2009011595A true MX2009011595A (es) 2009-12-08

Family

ID=39717534

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011595A MX2009011595A (es) 2007-04-27 2008-04-24 Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90.

Country Status (21)

Country Link
US (3) US20100113355A1 (es)
EP (2) EP2144932A1 (es)
JP (1) JP2010524485A (es)
KR (1) KR20100017387A (es)
CN (1) CN101679517A (es)
AR (1) AR066311A1 (es)
AU (1) AU2008244308A1 (es)
BR (1) BRPI0810827A2 (es)
CA (1) CA2685136A1 (es)
CL (1) CL2008001202A1 (es)
CR (1) CR11059A (es)
EA (1) EA200901441A1 (es)
EC (1) ECSP099765A (es)
GT (1) GT200900276A (es)
IL (1) IL201445A0 (es)
MA (1) MA31384B1 (es)
MX (1) MX2009011595A (es)
PE (1) PE20090728A1 (es)
TN (1) TN2009000442A1 (es)
TW (1) TW200902714A (es)
WO (2) WO2008132152A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
AU2015292498B2 (en) * 2014-07-23 2020-11-05 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
CN105652011B (zh) * 2014-11-20 2017-09-22 深圳市安群生物工程有限公司 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法
CN113845591B (zh) * 2018-10-30 2023-10-31 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732852A (en) 1981-11-20 1988-03-22 Cetus Corporation Site directed peptidase cleavage
US4670382A (en) 1983-12-02 1987-06-02 Temple University--of the Commonwealth System of Higher Education Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same
US4806465A (en) 1984-01-16 1989-02-21 Temple University Of The Commonwealth System Of Higher Education Cytoplasmic antigens of candida albicans and methods of using the same
GB8506373D0 (en) 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
GB8915019D0 (en) 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
ATE361313T1 (de) 2000-01-25 2007-05-15 Oklahoma Med Res Found Allgemeines verfahren zur rückfaltung rekombinanter proteine
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections
AU2001272001A1 (en) 2000-07-14 2002-01-30 Healthcite, Inc. Method and system for providing medical information
AU2002252179A1 (en) * 2001-03-01 2002-09-19 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
GB0127983D0 (en) 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
GB0409077D0 (en) * 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
US20080038267A1 (en) * 2004-07-02 2008-02-14 Neutec Pharma Limited Treatment Of Cancer
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition

Also Published As

Publication number Publication date
EP2152746A1 (en) 2010-02-17
IL201445A0 (en) 2010-06-16
ECSP099765A (es) 2009-12-28
CL2008001202A1 (es) 2008-12-19
WO2008132134A1 (en) 2008-11-06
JP2010524485A (ja) 2010-07-22
KR20100017387A (ko) 2010-02-16
CA2685136A1 (en) 2008-11-06
BRPI0810827A2 (pt) 2014-10-29
US20100113355A1 (en) 2010-05-06
CR11059A (es) 2009-11-20
AU2008244308A1 (en) 2008-11-06
US20100166758A1 (en) 2010-07-01
TN2009000442A1 (en) 2011-03-31
WO2008132152A1 (en) 2008-11-06
AR066311A1 (es) 2009-08-12
US7722869B2 (en) 2010-05-25
EA200901441A1 (ru) 2010-04-30
PE20090728A1 (es) 2009-07-02
TW200902714A (en) 2009-01-16
EP2144932A1 (en) 2010-01-20
US20090136484A1 (en) 2009-05-28
CN101679517A (zh) 2010-03-24
GT200900276A (es) 2010-05-21
WO2008132134A9 (en) 2009-07-09
MA31384B1 (fr) 2010-05-03

Similar Documents

Publication Publication Date Title
EP2987806A3 (en) Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
NZ597692A (en) Anti-IGF antibodies
NZ612319A (en) Single-chain multivalent binding proteins with effector function
TN2009000442A1 (en) Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
NZ701769A (en) Coiled coil and/or tether containing protein complexes and uses thereof
EP3683312A3 (en) Synthetic library of specific binding molecules
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
PE20120001A1 (es) Dominios variables simples anti-albumina de suero mejorados
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
NZ600278A (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
RS52790B (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
WO2008048545A3 (en) Molecules with reduced half-lives, compositions and uses thereof
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
WO2009004822A1 (ja) 抗Muc17抗体
WO2014090905A8 (en) Modified coiled coil type proteins having improved properties
MX2010000994A (es) Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6, dominio dimerico, metodo de inmunizacion, metodo de deteccion de rotavirus, composicion, metodos de prevencion y tratamiento de infecciones con rotavirus.
WO2008039838A3 (en) Synthetic streptococcus pneumoniae vaccine
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
WO2004108749A3 (en) Binding peptides: methods for their generation and use
DK1913020T3 (da) Immunogene konstrukter
AR082160A1 (es) Anticuerpos monoclonales dirigidos contra la toxina tetanica
ATE490270T1 (de) Zytokinderivate
WO2009060710A1 (ja) リポソームに抗体結合能を付与するペプチド、および当該ペプチドで修飾されたリポソーム